Louis Garguilo
ARTICLES BY LOUIS
-
![pharma cmo]( "Outsourcing Industry Awarded A Home")
3/31/2015Biopharma companies celebrating the CMO Awards with providers form deeper relationships, increased productivity, and the best outcomes from outsourcing activities.
-
![biologics]( "7 CEOs Say It's About The “Bios”: Biotechs, Biopharmaceuticals and Biosimilars")
3/9/2015The booming “Bios” are spurring expenditures, supply-and-demand questions and business decisions, and grabbing the attention of CEOs in 2015.
-
![contract biopharma, outsourcing]( "7 CEOs Say Outsourcing Advancing … On Swirling Currents (Part 1)")
3/3/2015How’s it going in the global BioPharma outsourcing industry? I reached out to 7 CEOs at global CROs/CDMOs for trends from the trenches – or at least the frontlines.
-
![12_0315_SupplyChain_pic]( "Biopharma Looks Into The Supply Chain Mirror: We're The Problem")
2/26/2015It’s like a scene from a Brothers Grimm folk tale. One late afternoon at an industry conference, a cross section of biopharmaceutical leaders gather in a room to take a hard look into a large mirror. It reflects that they — not their suppliers or service providers, as was assumed — are culpable for, and thus can control, many of the product reliability problems in their supply chains.
-
![Garguilo_Photo_2015]( "Naked Leadership: Stripped To Results In BioPharma")
2/24/2015An investigation into the modern-day minimalist verdict of leadership and it's accepted measurement. It’ll require a three-point thought experiment.
-
![Garguilo_Photo_2015]( "Misjudging Leadership In the BioPharma Industry")
2/13/2015We can learn about leadership from Lego. Or rather, this plastic building-block company can show us how little we actually understand the subject.
-
![pharma CDMO revenue]( "Profit For Good At Rottendorf Pharmaceuticals")
2/10/2015The desire to work for a larger cause, to somehow apply whatever we do for a living to benefit society, continues to rise. And that desire can also elevate company revenues.
-
![Garguilo_Photo_2015]( "Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance")
2/5/2015Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.
-
![Biosimilars Part 2: It’s All About Dollars Now]( "Biosimilars Part 2: It's All About Dollars Now")
2/2/2015Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.
-
![Biosimilars: A Brief Manifesto of Morality And Markets]( "Biosimilars: A Brief Manifesto of Morality And Markets")
1/26/2015As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.